Odd-Chain Triglyceride Fat Emulsion for CIP CIM Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Critical illness polyneuropathy (CIP) and critical illness myopathy (CIM) are significant complications in intensive care patients, leading to prolonged intensive therapy and increased treatment costs, with unclear causes and lacking effective therapies, and there is a need for nutritional methods to address these conditions.
Innovation Solution
A pharmaceutical preparation using a fat emulsion with triglycerides containing fatty acid residues with an odd number of carbon atoms, such as triheptanoin, which reduces the frequency or severity of CIP and CIM, and includes additional triglycerides with omega-3 and omega-6 fatty acids for enhanced nutritional support.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional fat emulsions (vegetable oils, MCT, fish oils) are used for parenteral nutrition, then nutritional supply is provided, but they fail to prevent or treat CIP and CIM effectively
Solution Approach 1:
The patent changes the chemical composition parameters of the fat emulsion by incorporating specific odd-numbered fatty acids (C5, C7, C9, C11, C13, C15) in defined proportions. This compositional parameter change transforms a conventional nutritional emulsion into a therapeutic preparation that specifically addresses CIP and CIM pathophysiology while maintaining nutritional function.
Solution Approach 2:
The invention creates a composite fat emulsion combining multiple triglyceride types (even-numbered, odd-numbered, medium-chain, long-chain) with specific fatty acid compositions. This composite structure integrates both nutritional support functions and therapeutic effects for preventing and treating critical illness polyneuropathy and myopathy.
2Duration of action of stationary object
If intensive care therapy is prolonged due to CIP/CIM complications, then patient survival is extended, but treatment costs and therapy duration increase significantly
Solution Approach 1:
The fat emulsion is designed to be administered prophylactically to intensive care patients before CIP and CIM fully develop. By providing early nutritional intervention with the specific triglyceride composition, the preparation prevents the onset of these complications, thereby avoiding prolonged therapy and rehabilitation delays while maintaining extended survival benefits.
3Reliability
If specific therapies for CIP/CIM are developed, then treatment effectiveness improves, but currently no specific therapies are available due to unclear causes
Solution Approach 1:
The patent addresses the unclear etiology by empirically determining the optimal fatty acid composition parameters that produce therapeutic effects. Through systematic variation of triglyceride composition (odd-numbered vs even-numbered, medium-chain vs long-chain), the invention identifies the specific parameter range that prevents and treats CIP and CIM, creating a evidence-based therapy despite incomplete understanding of underlying mechanisms.
Data Source
AI summary
The present invention relates to a pharmaceutical preparation for the prophylaxis and treatment of critical illness polyneuropathy (CIP) and critical illness myopathy (CIM). The invention further relates to an isotonic fat emulsion comprising at least one triglyceride that comprises at least one fatty acid group having an odd number of carbon atoms, wherein the fatty acid group comprises a carbon chain having 5 to 15 carbon atoms.